ArticleGenetic testing and molecular biomarkers2013
Prediction value of miR-483 and miR-214 in prognosis and multidrug resistance of esophageal squamous cell carcinoma.
Article in Genetic testing and molecular biomarkers, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Blood-based circulating microRNAs as potential biomarkers for predicting the prognosis of head and neck cancer-a systematic review.Clinical oral investigations · 2020Pooled it
- Circulating MicroRNAs as Prognostic Molecular Biomarkers in Human Head and Neck Cancer: A Systematic Review and Meta-Analysis.Disease markers · 2019Pooled it
- Prognostic Value of MicroRNAs in Esophageal Carcinoma: A Meta-Analysis.Clinical and translational gastroenterology · 2018Pooled it
- MiRNAs: main players of cancer drug resistance target ABC transporters.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Modulatory effects of miRNAs in doxorubicin resistance: A mechanistic view.Functional & integrative genomics · 2024Review
- Unveiling the Potential of Serum MiR-483-5p: A Promising Diagnostic and Prognostic Biomarker in OLP and OSCC Patients byCurrent pharmaceutical design · 2024Article
- Association of high miR-27a, miR-206, and miR-214 expression with poor patient prognosis and increased chemoresistance in triple-negative breast cancer.American journal of cancer research · 2023Article
- Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs.International journal of molecular sciences · 2022Review
- miRNAs as Biomarkers and Possible Therapeutic Strategies in Synovial Sarcoma.Frontiers in pharmacology · 2022Review
- Novel Implications of MicroRNAs, Long Non-coding RNAs and Circular RNAs in Drug Resistance of Esophageal Cancer.Frontiers in cell and developmental biology · 2021Review
- Circulating miR-19a-3p and miR-483-5p as Novel Diagnostic Biomarkers for the Early Diagnosis of Gastric Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- The Roles of miRNAs in Medulloblastoma: A Systematic Review.Journal of cancer prevention · 2019Review
- Article
- The anthelmintic drug flubendazole induces cell apoptosis and inhibits NF-κB signaling in esophageal squamous cell carcinoma.OncoTargets and therapy · 2019Article
- MiR-214 sensitizes human colon cancer cells to 5-FU by targeting Hsp27.Cellular & molecular biology letters · 2019Article
- Review
- MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus.Journal of translational medicine · 2018Article
- A 10‑microRNA prognosis scoring system in esophageal squamous cell carcinoma constructed using bioinformatic methods.Molecular medicine reports · 2018Article
- ABC Transporters and Their Role in the Neoadjuvant Treatment of Esophageal Cancer.International journal of molecular sciences · 2018Review
- Role of miR-483 in digestive tract cancers: from basic research to clinical value.Journal of Cancer · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsHere, we have investigated the role of miR-483 and miR-214 in the prognosis and multidrug resistance (MDR) of esophageal squamous cell carcinoma.
methodsThe expression of miR-483 and miR-214 was detected in 104 cases of esophageal cancer tissues and matched adjacent benign esophageal tissues by quantitative real-time PCR. The relation of microRNA expression with survival was statistically analyzed. The roles of miR-483 and miR-214 in MDR of esophageal squamous cell cancer cells were further evaluated.
resultsThe expression of miR-483 and miR-214 was found significantly upregulated in esophageal squamous cell cancer tissues. The expression levels of miR-483 and miR-214 showed an inverse correlation with overall survival. High expression of miR-483 and miR-214 might predict less chemotherapy effect. Downregulation of miR-483 and miR-214 could confer sensitivity of both P-glycoprotein-related and P-glycoprotein-nonrelated drugs to esophageal cancer cells, and it might induce increased accumulation of adriamycin (ADR) and decreased amount of ADR released.
conclusionsmiR-483 and miR-214 might play important roles in the pathogenesis of esophageal cancer and should be considered as potential targets for intervention in this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.